BioCryst Pharmaceuticals, Inc. (BCRX) Enters Overbought Territory - Tale of the Tape


Shutterstock photo

BioCryst Pharmaceuticals, Inc. ( BCRX ) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because BCRX is now in overbought territory with an RSI value of 70.50. Furthermore, estimates for the BioCryst Pharmaceuticals have been coming down, pushing it to a Zacks Rank #4 (Sell). This suggests that investors may better off exiting this stock before it falls back to Earth.

BIOCRYST PHARMA (BCRX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Investing Ideas , Stocks

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by